H.R. 1862 Regenerative Medicine Promotion Act
LEGISLATIVE INFORMATION PAGE
Bill Number: H.R. 1862
Title: Regenerative Medicine Promotion Act
Primary Sponsor: Bilbray (CA)/DeGette (CO)
Introduced: 5/12/11: Referred to House Energy and Commerce
To launch a national strategy to support regenerative medicine through funding for research and commercial development of regenerative medicine products and development of a regulatory environment that enables rapid approval of safe and effective products, and for other purposes.
Specifically, the Act would do the following:
- Require a report from the GAO that details ongoing Federal activities in regenerative medicine.
- Establish the Regenerative Medicine Coordinating Council – a public-private Council to devise a national strategy for the promotion of research into regenerative medicine and the development of drugs, biological products, medical devices, and biomaterials; identify and recommend policies to overcome barriers in research and product development; and specify priorities for research into regenerative medicine and the awarding of grants under the Act; Council to issue an annual report on the state of regenerative medicine.
- NIH Grants for Academic-Industry Collaboration – creates two translational research grant programs at NIH to nurture academic-industry collaboration
- Funds for non-profits or higher ed to conduct basic or preclinical research into regenerative medicine, if research is partly funded by private company.
- Grants to collaborative partnerships for R&D of regenerative medicine and the making of an (IND)/(IDE) application at FDA within 4-years.
- NIH Grants for Private Companies – to support product development in regenerative medicine through the existing Cures Acceleration Network.
- FDA Grants for Regulatory Research – to foster development of a clear, predictable regulatory pathway to enable speedy approval of safe and effective products, the Act authorizes FDA to conduct regulatory research to help in the approval of regenerative medicine products.
The Act does not authorize any new federal funding
|CHI Position:||Learn More about H.R. 1862:|
California Delegation Co-sponsors:
Eshoo, Anna (CA-14)
Farr, Sam (CA-17)